GSK's mRNA flu vaccine candidate advancing to Phase III is a positive pipeline catalyst, but revenue impact is years away. Monitor Phase III enrollment and interim data readouts. The Fast Track designation may accelerate regulatory review. Competitors include Moderna and Pfizer/BioNTech in the mRNA flu space.
Price Chart
Executive Summary
GSK announced positive Phase II data for its mRNA seasonal flu vaccine candidate (FLUm3HA.b-3NA), showing higher immune responses vs. standard and high-dose vaccines in younger and older adults. The candidate targets both HA and NA antigens, a novel approach for mRNA flu vaccines. GSK will initiate a Phase III efficacy trial in September 2026, and the FDA granted Fast Track designation in July 2026. This is a positive pipeline catalyst but remains early-stage with no near-term revenue impact.
Key Facts
- Phase II data showed higher immune responses vs. standard and high-dose flu vaccines in younger and older adults.
- GSK intends to start a Phase III efficacy trial in September 2026.
- FDA granted Fast Track designation in July 2026.
- Vaccine candidate targets both haemagglutinin (HA) and neuraminidase (NA) antigens.
- This will be the first Phase III trial of an mRNA flu vaccine designed to target both HA and NA.
- The vaccine candidate is not approved anywhere in the world.
Financial Impact
No financial figures disclosed. Pipeline milestone with potential future revenue if approved; Phase III trial costs are R&D expense.
Risk Factors
- Phase III trial may fail to meet efficacy or safety endpoints.
- mRNA flu vaccine market is competitive with Moderna and Pfizer/BioNTech advancing similar candidates.
- Regulatory approval and commercial launch are several years away.
- Vaccine not yet approved anywhere; no guarantee of eventual approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007998 |
| Document: 0001654954-26-007998-index-headers.html | 0001654954-26-007998 |
| Document: 0001654954-26-007998-index.html | 0001654954-26-007998 |
| Document: 0001654954-26-007998.txt | 0001654954-26-007998 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access